More questions than answers at the moment.
Hopefully a better picture will be painted at the webinar but I can’t help but think that details the ASX announcement are woefully inadequate.
Back in 2015 a licence agreement was struck with AstraZeneca. This included a US$2m signature payment and potential development, launch and sales milestones worth US$124m plus royalties.
But with this Medicxi partnership model, what has been disclosed is that Starpharma get no fees up front, no milestone payments and no royalties. Instead just the vagaries of a minority stake in a private entity. (If you think Starpharma’s disclosure has been poor over the years, what will this bring?)
The lack of detail in the formal ASX announcement is remarkable.
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-71
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.006(6.06%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $42.85K | 414.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 247015 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |